| 3001 | INPP5J levels | GCST90469618 | 4.91 |
| 3002 | Bone marrow fat fraction of lumbar vertebra 2 | GCST90652387 | 4.91 |
| 3003 | lymphocyte (absolute count, minimum, inv-norm transformed) | GCST90475429 | 4.91 |
| 3004 | KLK8/NECTIN4 ratio | GCST90315258 | 4.90 |
| 3005 | DAB2/LYN ratio | GCST90314365 | 4.90 |
| 3006 | WAS levels | GCST90471071 | 4.90 |
| 3007 | BA-exvivo rh area BA3a | GCST90003223 | 4.90 |
| 3008 | Bone density (confirmatory factor analysis Factor 19) | GCST90309353 | 4.90 |
| 3009 | HippSubfield rh volume presubiculum-body | GCST90002697 | 4.89 |
| 3010 | Cholesterol in Large VLDL | GCST90498123 | 4.89 |
| 3011 | Free Cholesterol to Total Lipids in Small LDL percentage | GCST90499635 | 4.89 |
| 3012 | Principal component-derived dietary pattern 33 | GCST90133038 | 4.88 |
| 3013 | PEAR1/PECAM1 ratio | GCST90315641 | 4.88 |
| 3014 | Shoulder lesions | FING00001303 | 4.88 |
| 3015 | Parental longevity (combined parental attained age, Martingale residuals) | GCST006697 | 4.88 |
| 3016 | PRAP1 levels | GCST90470312 | 4.88 |
| 3017 | SELPLG levels | GCST90470568 | 4.88 |
| 3018 | Substance dependence | GCST90018704 | 4.87 |
| 3019 | Saturated fatty acids to total fatty acids percentage | GCST90502684 | 4.87 |
| 3020 | rfMRI amplitudes (ICA100 node 45) | GCST90004633 | 4.87 |
| 3021 | Eosinophil count | GCST90025987 | 4.87 |
| 3022 | CDNF levels | GCST90468686 | 4.87 |
| 3023 | Extrapyramidal and movement disorders | FING00000527 | 4.87 |
| 3024 | MB levels | GCST90469869 | 4.87 |
| 3025 | Pregnenolone sulfate levels | GCST90199873 | 4.86 |
| 3026 | Cholesteryl Esters in Small VLDL | GCST90499786 | 4.86 |
| 3027 | CD1C/CD207 ratio | GCST90313745 | 4.86 |
| 3028 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502068 | 4.86 |
| 3029 | EFNA4/TNFRSF9 ratio | GCST90314606 | 4.85 |
| 3030 | ALDH1A1/SORD ratio | GCST90313248 | 4.85 |
| 3031 | Cheese consumption | GCST90133000 | 4.85 |
| 3032 | Shoulder lesions | Other soft tissue disorders | UKBB00000769 | 4.85 |
| 3033 | Primary biliary cholangitis | GCST003129 | 4.85 |
| 3034 | ANGPT1 levels | GCST90468300 | 4.84 |
| 3035 | NUDT5/SERPINB1 ratio | GCST90315581 | 4.84 |
| 3036 | Left-hemisphere salience/ventral attention network to hippocampus white-matter structural connectivity | GCST90302723 | 4.83 |
| 3037 | Lysoalkylphosphatidylcholine (O-24:1) levels | GCST90024813 | 4.83 |
| 3038 | SGSH levels | GCST90470615 | 4.83 |
| 3039 | F9/FURIN ratio | GCST90314747 | 4.83 |
| 3040 | Plasma X-24544 levels in chronic kidney disease | GCST90266757 | 4.83 |
| 3041 | HippSubfield lh volume presubiculum-head | GCST90002673 | 4.83 |
| 3042 | Acylcarnitine (18:2) levels | GCST90024623 | 4.82 |
| 3043 | Cerebrospinal fluid unidentified metabolite levels (HILIC Metabolomics ID: 3.04_132.06) | GCST90291582 | 4.82 |
| 3044 | LDL direct, adjusted by medication | Lipid or lipoprotein measurement | UKBB00000388 | 4.82 |
| 3045 | SCGB1A1 levels | GCST90470540 | 4.82 |
| 3046 | IDP dMRI ProbtrackX MD fmi | GCST90004230 | 4.80 |
| 3047 | CCL2 levels | GCST90468581 | 4.80 |
| 3048 | VSTM2L levels | GCST90471057 | 4.80 |
| 3049 | DTI autoptx L2 unc r tract | GCST90385192 | 4.80 |
| 3050 | SMOC2 levels | GCST90470683 | 4.78 |
| 3051 | TNFRSF1B levels | GCST90470911 | 4.78 |
| 3052 | ACE2/GGT1 ratio | GCST90313153 | 4.78 |
| 3053 | CALCOCO1/IRAG2 ratio | GCST90313604 | 4.78 |
| 3054 | Alzheimer's disease (MTAG) | GCST90449060 | 4.77 |
| 3055 | Total phospholipid levels in lipoprotein particles | GCST90500110 | 4.77 |
| 3056 | IDP T1 SIENAX brain-unnormalised volume | GCST90002435 | 4.77 |
| 3057 | aparc-DKTatlas lh volume supramarginal | GCST90002891 | 4.77 |
| 3058 | C4BPB levels | GCST90468499 | 4.77 |
| 3059 | Clonal haematopoiesis of indeterminate potential (TET2 mutation) | GCST90165281 | 4.77 |
| 3060 | FCER2/TNFRSF9 ratio | GCST90314791 | 4.77 |
| 3061 | CHI3L1/HSPG2 ratio | GCST90314043 | 4.76 |
| 3062 | Diacylglycerol (14:0_18:2) levels | GCST90024705 | 4.76 |
| 3063 | Operation code - cholecystectomy/gall bladder removal | Operations | UKBB00000554 | 4.75 |
| 3064 | XXYLT1 levels | GCST90243370 | 4.75 |
| 3065 | Myocardial fractal dimension (slice 7) | GCST90000293 | 4.75 |
| 3066 | Omega-6 fatty acid levels | GCST90502101 | 4.75 |
| 3067 | ENO2/TACC3 ratio | GCST90314670 | 4.74 |
| 3068 | BA-exvivo rh area MT | GCST90003232 | 4.74 |
| 3069 | F11R/GP1BA ratio | GCST90314722 | 4.74 |
| 3070 | CD7 levels | GCST90468649 | 4.74 |
| 3071 | Atopic/contact dermatitis due to other or unspecified (PheCode 939) | GCST90476289 | 4.73 |
| 3072 | Schizophrenia or delusion (more control exclusions) | FING00001278 | 4.73 |
| 3073 | TNFRSF11A levels | GCST90470902 | 4.73 |
| 3074 | OGFR levels | GCST90470118 | 4.73 |
| 3075 | SBSN levels | GCST90470531 | 4.73 |
| 3076 | Mean platelet volume | GCST90002395 | 4.73 |
| 3077 | Linoleic acid to total fatty acids percentage | GCST90498328 | 4.73 |
| 3078 | NBL1/NECTIN4 ratio | GCST90315514 | 4.72 |
| 3079 | Epstein-Barr virus ZEBRA antibody levels | GCST90006901 | 4.72 |
| 3080 | 1-(1-enyl-palmitoyl)-GPC (p-16:0) levels | GCST90199899 | 4.72 |
| 3081 | aparc-DKTatlas lh volume parsopercularis | GCST90002878 | 4.72 |
| 3082 | TPMT levels | GCST90470945 | 4.72 |
| 3083 | Free thyroxine levels within normal range in pregnancy | GCST90435196 | 4.72 |
| 3084 | Depression | Mental distress | UKBB00000165 | 4.72 |
| 3085 | Aniseed liking | GCST90094689 | 4.72 |
| 3086 | ADIPOQ levels | GCST90293086 | 4.71 |
| 3087 | Polyunsaturated fatty acids to total fatty acids percentage | GCST90502173 | 4.71 |
| 3088 | CTSF/SMPDL3A ratio | GCST90314316 | 4.71 |
| 3089 | aparc-DKTatlas rh area parsopercularis | GCST90003281 | 4.71 |
| 3090 | CXCL5/SPARC ratio | GCST90314355 | 4.71 |
| 3091 | ANGPT2 levels | GCST90468301 | 4.70 |
| 3092 | TOR1AIP1 levels | GCST90470935 | 4.70 |
| 3093 | CD20 on IgD- CD38- B cell | GCST90001755 | 4.70 |
| 3094 | LRCH4 levels | GCST90469791 | 4.70 |
| 3095 | DTI TBSS FA Posterior corona radiata R | GCST90384406 | 4.69 |
| 3096 | REG4/SPINK4 ratio | GCST90315766 | 4.69 |
| 3097 | Cholesteryl esters to total lipids ratio in small HDL | GCST90092947 | 4.69 |
| 3098 | HS6ST1 levels | GCST90469479 | 4.69 |
| 3099 | CD69/TIA1 ratio | GCST90313888 | 4.68 |
| 3100 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502398 | 4.68 |
| 3101 | VAMP5 levels | GCST90471024 | 4.68 |
| 3102 | GSTA3 levels | GCST90469412 | 4.68 |
| 3103 | Chronic hepatitis B infection | GCST90018584 | 4.68 |
| 3104 | Diacylglycerol_44:6_[M+H-H2O]1+ levels | GCST90060245 | 4.67 |
| 3105 | ThalamNuclei lh volume CM | GCST90002718 | 4.67 |
| 3106 | F2R/PDGFB ratio | GCST90314733 | 4.67 |
| 3107 | Hippocampal subfield right CA1 volume (head) | GCST90267961 | 4.67 |
| 3108 | Left-hemisphere visual network to left-hemisphere salience/ventral attention network white-matter structural connectivity | GCST90302651 | 4.67 |
| 3109 | APOM/MCAM ratio | GCST90313315 | 4.66 |
| 3110 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 22) | GCST90320841 | 4.66 |
| 3111 | X-12411 levels | GCST90200492 | 4.66 |
| 3112 | CDH2 levels | GCST90468673 | 4.66 |
| 3113 | DLL4 levels | GCST90469005 | 4.65 |
| 3114 | NCK2/VASH1 ratio | GCST90315526 | 4.65 |
| 3115 | Lymphocyte percentage | Blood count | UKBB00000412 | 4.65 |
| 3116 | HNRNPK/USP8 ratio | GCST90315070 | 4.64 |
| 3117 | Clonal hematopoiesis (overall) | GCST90435353 | 4.64 |
| 3118 | EDAR/SNAP23 ratio | GCST90314587 | 4.64 |
| 3119 | IDP dMRI ProbtrackX ICVF cgh r | GCST90004382 | 4.64 |
| 3120 | METAP2/USP8 ratio | GCST90315434 | 4.63 |
| 3121 | ENO2/TXNDC5 ratio | GCST90314671 | 4.63 |
| 3122 | CDH1/CST3 ratio | GCST90313946 | 4.63 |
| 3123 | Linoleic acid to total fatty acids percentage | GCST90502023 | 4.63 |
| 3124 | BCAM levels | GCST90468425 | 4.63 |
| 3125 | RTN4R levels | GCST90470508 | 4.62 |
| 3126 | Triglycerides to total lipids ratio in small VLDL | GCST90092979 | 4.62 |
| 3127 | PHLDB1 levels | GCST90470225 | 4.62 |
| 3128 | Platelet count | GCST90002402 | 4.62 |
| 3129 | Platelet count | Blood count | UKBB00000646 | 4.61 |
| 3130 | Myocardial fractal dimension (slice 2) | GCST90000288 | 4.61 |
| 3131 | IDP T1 SIENAX brain-normalised volume | GCST90002434 | 4.60 |
| 3132 | Triglycerides in large LDL (UKB data field 23536) | GCST90269633 | 4.60 |
| 3133 | CDH6/NTRK2 ratio | GCST90313962 | 4.59 |
| 3134 | Deep venous thrombosis | GCST90468122 | 4.59 |
| 3135 | CXCL11/ITGB1BP2 ratio | GCST90314335 | 4.59 |
| 3136 | Cooked vegetable intake | Diet | UKBB00000147 | 4.58 |
| 3137 | CD55/CHI3L1 ratio | GCST90313845 | 4.58 |
| 3138 | SMOC2 levels | GCST90060059 | 4.58 |
| 3139 | Docosahexaenoic acid to total fatty acids percentage (UKB data field 23457) | GCST90269554 | 4.58 |
| 3140 | IDP T1 FAST ROIs R cerebellum VI | GCST90002568 | 4.58 |
| 3141 | ITM2A levels | GCST90469653 | 4.57 |
| 3142 | SLAMF1 levels | GCST90274835 | 4.57 |
| 3143 | FGF19 levels | GCST90469220 | 4.57 |
| 3144 | 1-(1-enyl-palmitoyl)-2-linoleoyl-GPE (p-16:0/18:2) levels | GCST90200075 | 4.56 |
| 3145 | Principal component-derived dietary pattern 8 | GCST90133013 | 4.56 |
| 3146 | FCN2 levels | GCST90469204 | 4.55 |
| 3147 | Polyunsaturated fatty acids to total fatty acids percentage | GCST90502649 | 4.55 |
| 3148 | CD69/SNAP23 ratio | GCST90313886 | 4.55 |
| 3149 | F9/FETUB ratio | GCST90314746 | 4.55 |
| 3150 | DTI autoptx L3 fmi tract | GCST90385204 | 4.55 |
| 3151 | FKBP5/MITD1 ratio | GCST90314844 | 4.54 |
| 3152 | CD99L2 levels | GCST90468657 | 4.54 |
| 3153 | EDAR/IRAK4 ratio | GCST90314579 | 4.53 |
| 3154 | Cholesteryl esters to total lipids ratio in chylomicrons and extremely large VLDL | GCST90093043 | 4.53 |
| 3155 | Malignant neoplasm of oropharynx, excluding all cancers (controls excluding all cancers) | FING00000768 | 4.53 |
| 3156 | IL1R1 levels | GCST90469571 | 4.53 |
| 3157 | FABP5/PPCDC ratio | GCST90314763 | 4.53 |
| 3158 | wg lh intensity-contrast insula | GCST90003826 | 4.53 |
| 3159 | IDP dMRI TBSS ICVF Anterior limb of internal capsule L | GCST90004344 | 4.52 |
| 3160 | SERPINB8 levels | GCST90470592 | 4.52 |
| 3161 | LDLR/MEGF9 ratio | GCST90315310 | 4.52 |
| 3162 | All pneumoniae | FING00000065 | 4.51 |
| 3163 | DKKL1 levels | GCST90469000 | 4.51 |
| 3164 | Unspecified osteomyelitis (PheCode 710.19) | GCST90476224 | 4.51 |
| 3165 | Multi-trait sum score | GCST90270119 | 4.51 |
| 3166 | CNST/PRKAR1A ratio | GCST90314161 | 4.50 |
| 3167 | FABP2 levels | GCST90469174 | 4.49 |
| 3168 | MMP8/PGLYRP1 ratio | GCST90315465 | 4.49 |
| 3169 | CEBPB levels | GCST90468700 | 4.49 |
| 3170 | 1-stearoyl-2-oleoyl-GPS (18:0/18:1) levels | GCST90199652 | 4.49 |
| 3171 | CD84/DAG1 ratio | GCST90313910 | 4.49 |
| 3172 | EGFR/FAP ratio | GCST90314613 | 4.49 |
| 3173 | Interpolated Year when operation took place | Operations | UKBB00000372 | 4.49 |
| 3174 | IDP dMRI ProbtrackX ICVF ml r | GCST90004393 | 4.49 |
| 3175 | Percentage of FA2G1 in total neutral plasma glycans (GPn) (GP61) | GCST90668505 | 4.48 |
| 3176 | ADAMTSL4 levels | GCST90468229 | 4.48 |
| 3177 | Phospholipid levels in medium VLDL | GCST90092924 | 4.48 |
| 3178 | Pork consumption | GCST90132999 | 4.47 |
| 3179 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T305 | ECGA000305 | 4.47 |
| 3180 | Abdominal aortic calcification levels | GCST90134614 | 4.47 |
| 3181 | Saturated fatty acids to total fatty acids percentage | GCST90502700 | 4.47 |
| 3182 | PDLIM7/TBC1D23 ratio | GCST90315640 | 4.47 |
| 3183 | Wears glasses or contact lenses | Eyesight | UKBB00000907 | 4.47 |
| 3184 | Cholelithiasis and cholecystitis | digestive | UKBB00000133 | 4.46 |
| 3185 | Cholesterol in Small HDL | GCST90499358 | 4.46 |
| 3186 | ACY3 levels | GCST90468213 | 4.46 |
| 3187 | IGSF8 levels | GCST90469540 | 4.46 |
| 3188 | Mental and behavioural disorders due to use of other stimulants, including caffeine | FING00000811 | 4.46 |
| 3189 | CD209/CLEC4G ratio | GCST90313750 | 4.45 |
| 3190 | Cholesterol to total lipids in medium LDL percentage (UKB data field 23620) | GCST90269717 | 4.45 |
| 3191 | wg rh intensity-contrast medialorbitofrontal | GCST90003840 | 4.45 |
| 3192 | IDP dMRI TBSS ICVF Tapetum R | GCST90004373 | 4.45 |
| 3193 | DKK3/LTBP2 ratio | GCST90314487 | 4.45 |
| 3194 | Calcium levels | GCST90025990 | 4.44 |
| 3195 | Cirrhosis | GCST90319877 | 4.44 |
| 3196 | Lung volume | GCST90016668 | 4.44 |
| 3197 | Monounsaturated fatty acid levels | GCST90502359 | 4.43 |
| 3198 | Lymphocyte count | GCST90002388 | 4.43 |
| 3199 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T224 | ECGA000224 | 4.43 |
| 3200 | Platelet distribution width | GCST90002401 | 4.43 |
| 3201 | VLDL cholesterol levels (UKB data field 23403) | GCST90269500 | 4.42 |
| 3202 | IDP dMRI ProbtrackX L2 cgc l | GCST90004277 | 4.42 |
| 3203 | Omega-6 fatty acids to omega-3 fatty acids ratio | GCST90499199 | 4.42 |
| 3204 | PPP1R2/TMSB10 ratio | GCST90315721 | 4.42 |
| 3205 | T1 FreeSurfer a2009s lh S postcentral volume | GCST90384882 | 4.41 |
| 3206 | GFRA2/IL12A_IL12B ratio | GCST90314925 | 4.41 |
| 3207 | Low hand grip strength (60 years and older) (EWGSOP) | GCST90007527 | 4.41 |
| 3208 | Human herpes virus 7 U14 antibody levels | GCST90006909 | 4.41 |
| 3209 | Omega-6 fatty acid levels | GCST90502519 | 4.40 |
| 3210 | TTN levels | GCST90470984 | 4.40 |
| 3211 | BANK1/FOXO1 ratio | GCST90313456 | 4.40 |
| 3212 | CA13/TYMP ratio | GCST90313568 | 4.40 |
| 3213 | wg lh intensity-contrast paracentral | GCST90003808 | 4.40 |
| 3214 | T1 CAT volume L CingulateGyrusanteriordivision | GCST90384056 | 4.40 |
| 3215 | EFNA1/PIK3IP1 ratio | GCST90314598 | 4.40 |
| 3216 | IDP dMRI ProbtrackX ICVF fma | GCST90004385 | 4.40 |
| 3217 | Platelet count (UKB data field 30080) | GCST90468095 | 4.40 |
| 3218 | NUDT16 levels | GCST90470105 | 4.40 |
| 3219 | CDH3/NECTIN4 ratio | GCST90313952 | 4.39 |
| 3220 | IDP dMRI ProbtrackX ICVF str r | GCST90004399 | 4.39 |
| 3221 | aparc-DKTatlas rh volume fusiform | GCST90002898 | 4.39 |
| 3222 | Total Ceramide levels | GCST90025817 | 4.39 |
| 3223 | Phosphatidylethanolamine (38:4) levels | GCST90488261 | 4.39 |
| 3224 | APEX1/LSP1 ratio | GCST90313307 | 4.38 |
| 3225 | LGALS9 levels | GCST90469765 | 4.37 |
| 3226 | Asthma | GCST90018575 | 4.37 |
| 3227 | CTSD/PRCP ratio | GCST90314312 | 4.37 |
| 3228 | IDP dMRI ProbtrackX FA ifo l | GCST90003937 | 4.37 |
| 3229 | Reason for reducing amount of alcohol drunk - Health precaution | Alcohol | UKBB00000734 | 4.36 |
| 3230 | OXCT1 levels | GCST90470138 | 4.36 |
| 3231 | Triglycerides in IDL (UKB data field 23529) | GCST90269626 | 4.36 |
| 3232 | Female infertility, cervigal, vaginal, other or unspecified origin | FING00000538 | 4.35 |
| 3233 | Skin color (cheek, B value) | GCST90502779 | 4.35 |
| 3234 | ENO2/RWDD1 ratio | GCST90314667 | 4.35 |
| 3235 | Emphysema (PheCode 496.1) | GCST90476028 | 4.35 |
| 3236 | COL1A1/SOST ratio | GCST90314172 | 4.35 |
| 3237 | Job involved shift work | Employment history | UKBB00000382 | 4.34 |
| 3238 | CYB5R2 levels | GCST90468937 | 4.34 |
| 3239 | Placental weight (fetal genotype, adjusted for sex and gestational age) | GCST90275189 | 4.34 |
| 3240 | DNA methylation Hannum age acceleration | GCST90014289 | 4.33 |
| 3241 | Omega-6 fatty acids to total fatty acids percentage | GCST90502121 | 4.33 |
| 3242 | Cryptic phenotype that captures alpha-1-antitrypsin deficiency severity | GCST90101825 | 4.33 |
| 3243 | EIF4B/IPCEF1 ratio | GCST90314622 | 4.33 |
| 3244 | CCN2/DKK1 ratio | GCST90313710 | 4.33 |
| 3245 | APOB/APOA1 ratio | GCST90092810 | 4.33 |
| 3246 | IDP dMRI ProbtrackX FA ifo r | GCST90003938 | 4.33 |
| 3247 | Diseases of external ear | FING00000424 | 4.32 |
| 3248 | REST UKBBICA NODEamps25 0001 | GCST90385484 | 4.32 |
| 3249 | IDP T1 FAST ROIs L cerebellum IX | GCST90002584 | 4.31 |
| 3250 | FKBP1B/TGFB1 ratio | GCST90314836 | 4.31 |
| 3251 | Erythematous conditions (PheCode 695) | GCST90476177 | 4.31 |
| 3252 | CPA2/ITGB7 ratio | GCST90314207 | 4.31 |
| 3253 | CD244/GP1BA ratio | GCST90313766 | 4.31 |
| 3254 | Ratio of omega-6 fatty acids to total fatty acids | GCST90092935 | 4.30 |
| 3255 | wg lh intensity-contrast fusiform | GCST90003798 | 4.30 |
| 3256 | TF levels | GCST90470841 | 4.30 |
| 3257 | Testicular dysfunction (PheCode 257) | GCST90475696 | 4.29 |
| 3258 | STIP1/TMSB10 ratio | GCST90315890 | 4.29 |
| 3259 | TNFSF12 levels | GCST90470919 | 4.29 |
| 3260 | GFER/MAVS ratio | GCST90314919 | 4.29 |
| 3261 | LEPR/NTRK2 ratio | GCST90315313 | 4.29 |
| 3262 | Alpha-hydroxyisovalerate levels | GCST90199736 | 4.28 |
| 3263 | PLEKHO1 levels | GCST90470256 | 4.28 |
| 3264 | Polyunsaturated fatty acids to saturated fatty acids ratio | GCST90502596 | 4.28 |
| 3265 | CEP43/MPHOSPH8 ratio | GCST90314019 | 4.27 |
| 3266 | Free Cholesterol in VLDL | GCST90500217 | 4.27 |
| 3267 | SCG3 levels | GCST90470539 | 4.27 |
| 3268 | Gout | FING00000587 | 4.26 |
| 3269 | Hypertension | GCST90086091 | 4.26 |
| 3270 | Triglycerides to total lipids ratio in large LDL | GCST90092867 | 4.26 |
| 3271 | Total diffusion tensor imaging along the perivascular space index | GCST90455546 | 4.26 |
| 3272 | IDP dMRI TBSS ICVF Genu of corpus callosum | GCST90004329 | 4.25 |
| 3273 | LSP1/NADK ratio | GCST90315331 | 4.25 |
| 3274 | platelet count (mean, inv-norm transformed) | GCST90476299 | 4.25 |
| 3275 | AMBN levels | GCST90468287 | 4.25 |
| 3276 | Pure hypercholesterolaemia | FING00001230 | 4.25 |
| 3277 | Plasma lysine levels in chronic kidney disease | GCST90265459 | 4.24 |
| 3278 | CPQ levels | GCST90468846 | 4.24 |
| 3279 | aseg global volume EstimatedTotalIntraCranial | GCST90002597 | 4.24 |
| 3280 | Right-hemisphere dorsal attention network to amygdala white-matter structural connectivity | GCST90302811 | 4.24 |
| 3281 | SIL1 levels | GCST90470638 | 4.24 |
| 3282 | RBP7 levels | GCST90470440 | 4.24 |
| 3283 | Plasma 3-hydroxyhexanoate levels in chronic kidney disease | GCST90264498 | 4.23 |
| 3284 | rfMRI connectivity (ICA100 edge 383) | GCST90005236 | 4.23 |
| 3285 | Cholesteryl esters in medium LDL (UKB data field 23541) | GCST90269638 | 4.22 |
| 3286 | PLA2G4A/SNAP29 ratio | GCST90315669 | 4.22 |
| 3287 | F-sodas liking (derived food-liking factor) | GCST90094842 | 4.22 |
| 3288 | FLT3 levels | GCST90469251 | 4.22 |
| 3289 | X-21353 metabolite level | GCST90616708 | 4.22 |
| 3290 | Lung cancer | GCST90018655 | 4.21 |
| 3291 | LAT levels | GCST90469741 | 4.21 |
| 3292 | Activities undertaken to treat anxiety | Anxiety | UKBB00000009 | 4.21 |
| 3293 | Pain in limb (PheCode 773) | GCST90476270 | 4.21 |
| 3294 | Reticulocyte count | GCST90025972 | 4.20 |
| 3295 | PARP1/TCL1A ratio | GCST90315602 | 4.20 |
| 3296 | SCPEP1 levels | GCST90470553 | 4.20 |
| 3297 | ADAM15 levels | GCST90468217 | 4.20 |
| 3298 | CCL19 levels | GCST90468571 | 4.20 |
| 3299 | Diseases of liver | FING00000425 | 4.20 |
| 3300 | Mean volume of bilateral amygdala | GCST90474992 | 4.19 |
| 3301 | PEAR1/SCARF1 ratio | GCST90315642 | 4.19 |
| 3302 | FLT3LG levels | GCST90469250 | 4.19 |
| 3303 | Amyotrophic lateral sclerosis | GCST90027164 | 4.19 |
| 3304 | AIFM1/EGF ratio | GCST90313219 | 4.18 |
| 3305 | Omega-3 fatty acids to total fatty acids percentage | GCST90502081 | 4.18 |
| 3306 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 82) | GCST90320645 | 4.18 |
| 3307 | ANGPTL4 levels | GCST90468305 | 4.18 |
| 3308 | Lymphocyte count | GCST004627 | 4.17 |
| 3309 | GBP1 levels | GCST90469311 | 4.17 |
| 3310 | TXNDC15 levels | GCST90470990 | 4.17 |
| 3311 | APP/BIN2 ratio | GCST90313316 | 4.16 |
| 3312 | Chronic myeloproliferative disease | FING00000294 | 4.16 |
| 3313 | CSF1/IL10RB ratio | GCST90314284 | 4.16 |
| 3314 | CD22/SEMA7A ratio | GCST90313759 | 4.15 |
| 3315 | Red cell distribution width | GCST90002404 | 4.15 |
| 3316 | CRADD/FKBP4 ratio | GCST90314238 | 4.14 |
| 3317 | Age-related macular degeneration | GCST90086111 | 4.14 |
| 3318 | IL5RA/TNFRSF13B ratio | GCST90315164 | 4.14 |
| 3319 | Mean bone marrow fat fraction of lumbar vertebrae 1-5 | GCST90652391 | 4.13 |
| 3320 | Pain medicine use during menstruation | GCST006637 | 4.13 |
| 3321 | C1QL2 levels | GCST90468487 | 4.13 |
| 3322 | ACYP2 levels | GCST90240187 | 4.13 |
| 3323 | Free cholesterol to total lipids in very small VLDL percentage (UKB data field 23607) | GCST90269704 | 4.13 |
| 3324 | VLDL cholesterol levels | GCST90092996 | 4.13 |
| 3325 | Mean platelet (thrombocyte) volume | Blood count | UKBB00000450 | 4.13 |
| 3326 | SPARC levels | GCST90470718 | 4.12 |
| 3327 | Platelet distribution width | Blood count | UKBB00000648 | 4.12 |
| 3328 | EDAR/SERPINB1 ratio | GCST90314586 | 4.12 |
| 3329 | FLT4/ICAM2 ratio | GCST90314860 | 4.12 |
| 3330 | CXCL6/DFFA ratio | GCST90314357 | 4.12 |
| 3331 | GNS levels | GCST90088460 | 4.12 |
| 3332 | CLEC7A levels | GCST90468778 | 4.12 |
| 3333 | Basophil percentage of white cells variance | GCST90565688 | 4.12 |
| 3334 | CALCOCO1/VPS53 ratio | GCST90313612 | 4.12 |
| 3335 | Carboplatin drug response (IC50) | GCST90011783 | 4.11 |
| 3336 | ACY1/SCLY ratio | GCST90313165 | 4.11 |
| 3337 | CST3/EFEMP1 ratio | GCST90314292 | 4.11 |
| 3338 | NME3 levels | GCST90470055 | 4.11 |
| 3339 | BAG6/BMP6 ratio | GCST90313450 | 4.10 |
| 3340 | PDLIM7/SRC ratio | GCST90315639 | 4.10 |
| 3341 | C1QTNF9 levels | GCST90468491 | 4.09 |
| 3342 | Acetone levels (UKB data field 23477) | GCST90269574 | 4.09 |
| 3343 | aseg rh volume VentralDC | GCST90002644 | 4.09 |
| 3344 | TXN levels | GCST90470995 | 4.09 |
| 3345 | Heart failure with preserved EF [Diastolic heart failure] (PheCode 428.4) | GCST90475984 | 4.09 |
| 3346 | Atherosclerosis, excluding cerebral and coronary sclerosis | FING00000123 | 4.08 |
| 3347 | Operation code - squint correction | Operations | UKBB00000566 | 4.08 |
| 3348 | Phosphatidylcholine (40:8) levels | GCST90025538 | 4.08 |
| 3349 | Phospholipids in small VLDL (UKB data field 23511) | GCST90269608 | 4.08 |
| 3350 | Pneumoconiosis due to other inorganic dusts | FING00001173 | 4.08 |
| 3351 | Skin and soft tissue infections | GCST90013411 | 4.08 |
| 3352 | CD300LF levels | GCST90468622 | 4.07 |
| 3353 | SERPINB1/SERPINB9 ratio | GCST90315827 | 4.06 |
| 3354 | LCN2 levels | GCST90469747 | 4.06 |
| 3355 | DARS1/MAP4K5 ratio | GCST90314404 | 4.06 |
| 3356 | CDH1/CDH17 ratio | GCST90313945 | 4.06 |
| 3357 | EBAG9/TBCC ratio | GCST90314568 | 4.06 |
| 3358 | Omega-6 fatty acids to total fatty acids percentage | GCST90502127 | 4.05 |
| 3359 | IDP dMRI ProbtrackX OD slf r | GCST90004472 | 4.05 |
| 3360 | LILRB4 levels | GCST90426708 | 4.05 |
| 3361 | ABHD14B/CRADD ratio | GCST90313141 | 4.05 |
| 3362 | IGLC2 levels | GCST90469536 | 4.05 |
| 3363 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T222 | ECGA000222 | 4.04 |
| 3364 | QDPR levels | GCST90470400 | 4.04 |
| 3365 | SFTPA2 levels | GCST90470613 | 4.04 |
| 3366 | WIF1 levels | GCST90471078 | 4.04 |
| 3367 | Tea difference liking | GCST90094855 | 4.04 |
| 3368 | APP levels | GCST90468344 | 4.03 |
| 3369 | DOK2/PPP1R2 ratio | GCST90314537 | 4.03 |
| 3370 | Lymphocyte count (UKB data field 30120) | GCST90468082 | 4.02 |
| 3371 | HBEGF levels | GCST90012067 | 4.02 |
| 3372 | eGFR in diabetes mellitus (loose) (minimal adjustment) | GCST90624783 | 4.02 |
| 3373 | Docosahexaenoic acid to total fatty acids percentage | GCST90502280 | 4.02 |
| 3374 | GLOD4/S100A4 ratio | GCST90314944 | 4.02 |
| 3375 | TNFSF12/TNFSF13 ratio | GCST90315941 | 4.01 |
| 3376 | ABL1/PDLIM7 ratio | GCST90313150 | 4.01 |
| 3377 | LAT2 levels | GCST90469739 | 4.01 |
| 3378 | FKBP4/RWDD1 ratio | GCST90314840 | 4.01 |
| 3379 | PTPN6/YES1 ratio | GCST90315750 | 4.01 |
| 3380 | PPCDC levels | GCST90470290 | 4.01 |
| 3381 | CLEC14A/TNFRSF21 ratio | GCST90314082 | 4.01 |
| 3382 | Neutrophil percentage of white cells variance | GCST90565701 | 4.00 |
| 3383 | Bioavailable testosterone levels | GCST90012104 | 4.00 |
| 3384 | RAB10 levels | GCST90470403 | 4.00 |
| 3385 | CA3/HMBS ratio | GCST90313584 | 4.00 |
| 3386 | Cholesterol to total lipids in medium VLDL percentage (UKB data field 23595) | GCST90269692 | 4.00 |
| 3387 | Multiple myeloma, Monoclonal gammopathy of undetermined significance (MGUS), excluding all cancers (controls excluding all cancers) | FING00000846 | 4.00 |
| 3388 | DAPK2 levels | GCST90240877 | 3.99 |
| 3389 | Rhodanobacter abundance in stool | GCST90032536 | 3.99 |
| 3390 | QC SWI-to-T1 linear alignment discrepancy | GCST90006352 | 3.99 |
| 3391 | GSTA1/KRT18 ratio | GCST90314993 | 3.99 |
| 3392 | Cholesteryl esters to total lipids in large VLDL percentage (UKB data field 23591) | GCST90269688 | 3.99 |
| 3393 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T381 | ECGU000381 | 3.98 |
| 3394 | RGS18 levels | GCST90242617 | 3.98 |
| 3395 | CALCOCO1/PDLIM7 ratio | GCST90313607 | 3.98 |
| 3396 | BST2 levels | GCST90468475 | 3.97 |
| 3397 | RBP5 levels | GCST90470439 | 3.97 |
| 3398 | COL18A1/RETN ratio | GCST90314170 | 3.97 |
| 3399 | EIF4G1/MAVS ratio | GCST90314636 | 3.97 |
| 3400 | LPCAT2/SERPINB8 ratio | GCST90315328 | 3.97 |
| 3401 | Phospholipid levels in small VLDL | GCST90092976 | 3.96 |
| 3402 | FOLH1 levels | GCST90469258 | 3.96 |
| 3403 | ANPEP/CXADR ratio | GCST90313272 | 3.96 |
| 3404 | Right-hemisphere somatomotor network to pallidum white-matter structural connectivity | GCST90302797 | 3.95 |
| 3405 | ICAM2 levels | GCST90469499 | 3.95 |
| 3406 | Varicose veins | GCST90086144 | 3.95 |
| 3407 | Degree of unsaturation | GCST90502753 | 3.95 |
| 3408 | aseg global volume CC-Central | GCST90002609 | 3.94 |
| 3409 | FASLG levels | GCST90469191 | 3.94 |
| 3410 | LCAT levels | GCST90469745 | 3.94 |
| 3411 | Saturated fatty acids levels | GCST90502671 | 3.93 |
| 3412 | Skin color (cheek, ITA value) | GCST90502780 | 3.93 |
| 3413 | CRTAM/ICAM3 ratio | GCST90314276 | 3.93 |
| 3414 | FLT3LG levels | GCST90274791 | 3.93 |
| 3415 | CD72 levels | GCST90468646 | 3.93 |
| 3416 | Metabolic disorder, other/unspecified | FING00000815 | 3.93 |
| 3417 | Linoleic acid levels | GCST90502295 | 3.92 |
| 3418 | DAG1/DKK1 ratio | GCST90314373 | 3.92 |
| 3419 | FYB1/PPP1R12A ratio | GCST90314913 | 3.92 |
| 3420 | Multi-trait sex score | GCST90270116 | 3.91 |
| 3421 | MAVS/SCAMP3 ratio | GCST90315396 | 3.91 |
| 3422 | ACP5 levels | GCST90468203 | 3.91 |
| 3423 | Right-hemisphere visual network to caudate white-matter structural connectivity | GCST90302782 | 3.91 |
| 3424 | Sarcoidosis | FING00001275 | 3.91 |
| 3425 | Ever sought or received professional help for mental distress | Mental distress | UKBB00000222 | 3.91 |
| 3426 | Diacylglycerol_34:3_[M+H-H2O]1+ levels | GCST90060177 | 3.91 |
| 3427 | EFEMP1/IL18BP ratio | GCST90314596 | 3.90 |
| 3428 | Fracture of forearm | GCST90281273 | 3.90 |
| 3429 | Glucose levels | GCST90092819 | 3.90 |
| 3430 | Ceramide_40:1_[M-H]1- levels | GCST90060198 | 3.90 |
| 3431 | Illnesses of father - High blood pressure | Family history | UKBB00000343 | 3.90 |
| 3432 | IMPA1/TBCC ratio | GCST90315175 | 3.90 |
| 3433 | MYOC/NOTCH3 ratio | GCST90315507 | 3.90 |
| 3434 | Alkaline phosphatase (UKB data field 30610) | GCST90468060 | 3.89 |
| 3435 | BACH1/DIABLO ratio | GCST90313437 | 3.89 |
| 3436 | DTI TBSS L3 Posterior corona radiata R | GCST90384550 | 3.89 |
| 3437 | Asphyxia and hypoxemia (PheCode 1013) | GCST90475559 | 3.89 |
| 3438 | Recent feelings of inadequacy | Depression | UKBB00000739 | 3.88 |
| 3439 | Plasma sphingomyelin (d18:1/25:0, d19:0/24:1, d20:1/23:0, d19:1/24:0)* levels in chronic kidney disease | GCST90265971 | 3.88 |
| 3440 | MUC2 levels | GCST90469965 | 3.88 |
| 3441 | Citrate levels (UKB data field 23473) | GCST90269570 | 3.88 |
| 3442 | AK1/NSFL1C ratio | GCST90313224 | 3.88 |
| 3443 | MENT levels | GCST90469886 | 3.88 |
| 3444 | VSTM2B levels | GCST90471056 | 3.88 |
| 3445 | HHEX levels | GCST90469451 | 3.87 |
| 3446 | ART3/GPC1 ratio | GCST90313361 | 3.87 |
| 3447 | HEXIM1/NT5C3A ratio | GCST90315048 | 3.87 |
| 3448 | CD40/CRELD2 ratio | GCST90313811 | 3.87 |
| 3449 | GP6/LGALS8 ratio | GCST90314964 | 3.87 |
| 3450 | aparc-Desikan rh area parsopercularis | GCST90003124 | 3.87 |
| 3451 | PLSCR3 levels | GCST90470261 | 3.87 |
| 3452 | CD20 on IgD- CD27- B cell | GCST90001754 | 3.87 |
| 3453 | Fluid intelligence score | Fluid intelligence / reasoning | UKBB00000250 | 3.87 |
| 3454 | PAMR1/RARRES2 ratio | GCST90315595 | 3.87 |
| 3455 | LAMA4 levels | GCST90469731 | 3.87 |
| 3456 | Nonspecific elevation of levels of transaminase or lactic acid dehydrogenase [LDH] (PheCode 573.6) | GCST90476094 | 3.86 |
| 3457 | PM20D1 levels | GCST90470268 | 3.86 |
| 3458 | ARNT levels | GCST90468367 | 3.86 |
| 3459 | BTN2A1/CSF1 ratio | GCST90313541 | 3.86 |
| 3460 | Total Phosphatidylcholine levels | GCST90025204 | 3.86 |
| 3461 | FABP4/FGF21 ratio | GCST90314758 | 3.85 |
| 3462 | IPCEF1/SERPINE1 ratio | GCST90315184 | 3.85 |
| 3463 | QDPR/THOP1 ratio | GCST90315757 | 3.85 |
| 3464 | DDC levels | GCST90468967 | 3.85 |
| 3465 | Cancer (UKB data field 2453) | GCST90043628 | 3.84 |
| 3466 | HRC levels | GCST90469475 | 3.84 |
| 3467 | DECR1 levels | GCST90468978 | 3.83 |
| 3468 | ANGPT1/DKK1 ratio | GCST90313263 | 3.83 |
| 3469 | platelet count (maximum, inv-norm transformed) | GCST90476296 | 3.83 |
| 3470 | TMSB10/ZBTB16 ratio | GCST90315926 | 3.81 |
| 3471 | TNFRSF6B levels | GCST90470914 | 3.81 |
| 3472 | ENAH levels | GCST90469106 | 3.81 |
| 3473 | NAAA/SMPD1 ratio | GCST90315510 | 3.81 |
| 3474 | mean corpuscular hemoglobin concentration (MCHC, mean, inv-norm transformed) | GCST90475458 | 3.81 |
| 3475 | VEGFC levels | GCST90471036 | 3.80 |
| 3476 | Seen a psychiatrist for nerves, anxiety, tension or depression | Mental health | UKBB00000764 | 3.80 |
| 3477 | Prescriptions - metformin | biguanides,diabetes | UKBB00000692 | 3.80 |
| 3478 | Prescriptions - biguanides|diabetes | UKBB00000671 | 3.80 |
| 3479 | GDF15 levels | GCST90469321 | 3.80 |
| 3480 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T107 | ECGU000107 | 3.80 |
| 3481 | IDP dMRI TBSS ISOVF Anterior corona radiata L | GCST90004500 | 3.80 |
| 3482 | IDP dMRI TBSS L3 Posterior limb of internal capsule R | GCST90004189 | 3.79 |
| 3483 | Breakthrough COVID-19 susceptibility after at least one dose of a COVID-19 vaccine | GCST90448695 | 3.79 |
| 3484 | VSIR levels | GCST90471053 | 3.79 |
| 3485 | Physical activity (Relative amplitude) | GCST90061432 | 3.79 |
| 3486 | TOMM20 levels | GCST90470931 | 3.78 |
| 3487 | CLEC1B/EGF ratio | GCST90314089 | 3.78 |
| 3488 | Valine levels | GCST90243453 | 3.78 |
| 3489 | AmygNuclei rh volume Accessory-Basal-nucleus | GCST90002660 | 3.78 |
| 3490 | MGLL/STK4 ratio | GCST90315443 | 3.77 |
| 3491 | Attention deficit hyperactivity disorder | GCST90568441 | 3.77 |
| 3492 | OPTC levels | GCST90470128 | 3.77 |
| 3493 | Red cell distribution width | GCST006804 | 3.77 |
| 3494 | Citrate levels | GCST90243442 | 3.76 |
| 3495 | DBI/EDAR ratio | GCST90314408 | 3.76 |
| 3496 | IL3RA levels | GCST90469596 | 3.76 |
| 3497 | Educational attainment | GCST003496 | 3.76 |
| 3498 | EDN1 levels | GCST90469073 | 3.76 |
| 3499 | DTI autoptx L2 str l tract | GCST90385189 | 3.76 |
| 3500 | AmygNuclei rh volume Medial-nucleus | GCST90002663 | 3.76 |
| 3501 | KHK levels | GCST90469675 | 3.76 |
| 3502 | PTPN1/TDRKH ratio | GCST90315745 | 3.75 |
| 3503 | HSD11B1 levels | GCST90469482 | 3.75 |
| 3504 | Oral glucose tolerance test-0h | GCST90297788 | 3.75 |
| 3505 | 1-stearoyl-2-arachidonoyl-GPI (18:0/20:4) levels | GCST90199649 | 3.74 |
| 3506 | Plasma cystathionine levels in chronic kidney disease | GCST90264974 | 3.74 |
| 3507 | SUMF2 levels | GCST90470784 | 3.74 |
| 3508 | Abdominal aortic aneurysm (AAA) | FING00000001 | 3.74 |
| 3509 | Bone marrow fat fraction of thoracic vertebra 10 | GCST90652382 | 3.74 |
| 3510 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T306 | ECGA000306 | 3.73 |
| 3511 | Reason for glasses/contact lenses - For 'astigmatism' | Eyesight | UKBB00000733 | 3.73 |
| 3512 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T446 | ECGA000446 | 3.73 |
| 3513 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T382 | ECGU000382 | 3.72 |
| 3514 | IDP dMRI TBSS ICVF Posterior corona radiata L | GCST90004354 | 3.72 |
| 3515 | CCL13/CCL8 ratio | GCST90313676 | 3.72 |
| 3516 | Cholesteryl esters to total lipids ratio in very large VLDL | GCST90093019 | 3.72 |
| 3517 | QC dMRI-to-T1 linear alignment discrepancy | GCST90006351 | 3.71 |
| 3518 | eGFR in diabetes mellitus (full adjustment) | GCST90624786 | 3.71 |
| 3519 | BIN2/PDLIM7 ratio | GCST90313509 | 3.71 |
| 3520 | KLB levels | GCST90469693 | 3.71 |
| 3521 | Brainstem global volume Midbrain | GCST90002767 | 3.71 |
| 3522 | ARHGAP30 levels | GCST90468354 | 3.71 |
| 3523 | Right ventricular peak atrial filling rate | GCST90268119 | 3.71 |
| 3524 | Self-reported risk-taking behaviour | GCST006810 | 3.71 |
| 3525 | Polyunsaturated fatty acids to total fatty acids percentage | GCST90499299 | 3.70 |
| 3526 | CTF1 levels | GCST90468901 | 3.70 |
| 3527 | IDP dMRI TBSS L2 Posterior thalamic radiation R | GCST90004151 | 3.69 |
| 3528 | TNIP1 levels | GCST90470925 | 3.69 |
| 3529 | CLEC1B/RWDD1 ratio | GCST90314102 | 3.69 |
| 3530 | CLEC1B/VTA1 ratio | GCST90314107 | 3.69 |
| 3531 | MASP1 levels | GCST90469863 | 3.69 |
| 3532 | CD48/SLAMF7 ratio | GCST90313842 | 3.68 |
| 3533 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 65) | GCST90320884 | 3.68 |
| 3534 | CCL8 levels | GCST90422346 | 3.67 |
| 3535 | Vitamin D levels | GCST005367 | 3.67 |
| 3536 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T437 | ECGA000437 | 3.67 |
| 3537 | IDP T1 FAST ROIs L cerebellum V | GCST90002564 | 3.67 |
| 3538 | Hip circumference | GCST90278633 | 3.66 |
| 3539 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 6) | GCST90320569 | 3.66 |
| 3540 | METAP1D/PLXNA4 ratio | GCST90315427 | 3.66 |
| 3541 | Wears glasses or contact lenses (UKB data field 2207) | GCST90042875 | 3.65 |
| 3542 | CCL4 levels | GCST004433 | 3.65 |
| 3543 | SKAP2 levels | GCST90470646 | 3.65 |
| 3544 | Platelet count | GCST90002358 | 3.65 |
| 3545 | SLC35G2 levels | GCST90242857 | 3.65 |
| 3546 | Total fatty acid levels | GCST90502723 | 3.65 |
| 3547 | Statin-associated type 2 diabetes mellitus | GCST90652517 | 3.65 |
| 3548 | Phospholipids to total lipids ratio in medium VLDL | GCST90092925 | 3.65 |
| 3549 | GDF2 levels | GCST90469322 | 3.64 |
| 3550 | Feeling fed-up | GCST006947 | 3.64 |
| 3551 | Calcium | Blood biochemistry | UKBB00000114 | 3.64 |
| 3552 | Mean volume of bilateral amygdala | GCST90474899 | 3.64 |
| 3553 | STK11 levels | GCST90470765 | 3.64 |
| 3554 | ANGPTL2 levels | GCST90468303 | 3.64 |
| 3555 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T289 | ECGA000289 | 3.64 |
| 3556 | Volume of right accessory basal nucleus | GCST90475006 | 3.64 |
| 3557 | EGF/MANF ratio | GCST90314609 | 3.64 |
| 3558 | Linoleic acid to total fatty acids percentage | GCST90502336 | 3.63 |
| 3559 | CEBPB/NADK ratio | GCST90314006 | 3.63 |
| 3560 | Sphingomyelins levels (UKB data field 23438) | GCST90269535 | 3.63 |
| 3561 | BCAN/DPP6 ratio | GCST90313478 | 3.62 |
| 3562 | FUT3 or FUT5 levels | GCST90469280 | 3.62 |
| 3563 | Basophil count variance | GCST90565682 | 3.62 |
| 3564 | Lysoalkylphosphatidylcholine (O-22:1) levels | GCST90024196 | 3.62 |
| 3565 | PMVK/RHOC ratio | GCST90315697 | 3.62 |
| 3566 | Valine levels | GCST90500177 | 3.62 |
| 3567 | Sphingomyelin levels | GCST90092982 | 3.61 |
| 3568 | EPHA1 levels | GCST90469129 | 3.61 |
| 3569 | Glycated haemoglobin HbA1c levels (UKB data field 30750) | GCST90468072 | 3.61 |
| 3570 | EDAR/ERBIN ratio | GCST90314575 | 3.61 |
| 3571 | Cholesterol_[M+H-H2O]1+ levels | GCST90060133 | 3.61 |
| 3572 | EBAG9/EDAR ratio | GCST90314563 | 3.61 |
| 3573 | Triglycerides to total lipids ratio in small LDL | GCST90092967 | 3.60 |
| 3574 | DTI autoptx FA ptr l tract | GCST90385131 | 3.60 |
| 3575 | Other disorders of skin and subcutaneous tissue, not elsewhere classified | FING00001036 | 3.60 |
| 3576 | Gut bacterial pathway abundance (PYRIDNUCSYN.PWY..NAD.biosynthesis.I..from.aspartate.) | GCST90027638 | 3.60 |
| 3577 | Ascites (non malignant) (PheCode 572) | GCST90476090 | 3.60 |
| 3578 | Left-hemisphere visual network to right-hemisphere limbic network white-matter structural connectivity | GCST90302659 | 3.60 |
| 3579 | Mandibular retrognathia | FING00000784 | 3.60 |
| 3580 | Non-cancer illness code, self-reported - hayfever/allergic rhinitis | Medical conditions | UKBB00000513 | 3.59 |
| 3581 | COX5B/GFER ratio | GCST90314200 | 3.59 |
| 3582 | Ulcerative colitis (PheCode 555.2) | GCST90044155 | 3.59 |
| 3583 | wg rh intensity-contrast rostralanteriorcingulate | GCST90003852 | 3.58 |
| 3584 | 5-hydroxyindole sulfate levels | GCST90200050 | 3.58 |
| 3585 | IDP dMRI TBSS ICVF Anterior corona radiata R | GCST90004349 | 3.58 |
| 3586 | aseg global volume BrainSeg | GCST90002590 | 3.58 |
| 3587 | THBD levels | GCST90470853 | 3.57 |
| 3588 | Kidney transplant status | FING00000710 | 3.57 |
| 3589 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T381 | ECGA000381 | 3.57 |
| 3590 | Carcinoma in situ of breast, intraductal (controls excluding all cancers) | FING00000240 | 3.57 |
| 3591 | IDP dMRI ProbtrackX OD slf l | GCST90004471 | 3.57 |
| 3592 | Alcohol liking | GCST90094688 | 3.56 |
| 3593 | DTI TBSS MD Anterior corona radiata L | GCST90384595 | 3.56 |
| 3594 | PPM1B levels | GCST90470296 | 3.56 |
| 3595 | Autoimmune polyglandular failure | FING00000135 | 3.56 |
| 3596 | Total lipids in medium VLDL | GCST90498994 | 3.56 |
| 3597 | COL2A1 levels | GCST90468816 | 3.56 |
| 3598 | SEMA3G levels | GCST90242746 | 3.56 |
| 3599 | CA5A levels | GCST90468514 | 3.56 |
| 3600 | ESAM/SCARF1 ratio | GCST90314715 | 3.56 |
| 3601 | Ever depressed for a whole week | Mental health | UKBB00000214 | 3.56 |
| 3602 | CKAP4/LAMP3 ratio | GCST90314073 | 3.55 |
| 3603 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T382 | ECGA000382 | 3.55 |
| 3604 | Other (seronegative) rheumatoid arthritis, wide | FING00000917 | 3.55 |
| 3605 | C9 Carnitine levels in chronic kidney disease | GCST90257682 | 3.55 |
| 3606 | Chronotype | GCST003837 | 3.54 |
| 3607 | Free cholesterol levels in medium HDL | GCST90132679 | 3.54 |
| 3608 | MITD1/SNX9 ratio | GCST90315454 | 3.54 |
| 3609 | CEACAM8/PGLYRP1 ratio | GCST90314003 | 3.54 |
| 3610 | CNTN5/ROBO2 ratio | GCST90314166 | 3.54 |
| 3611 | CSTB levels | GCST90468898 | 3.53 |
| 3612 | MDK levels | GCST90469877 | 3.53 |
| 3613 | ALDH1A1/CA2 ratio | GCST90313243 | 3.53 |
| 3614 | Female infertility | FING00000536 | 3.53 |
| 3615 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T380 | ECGA000380 | 3.53 |
| 3616 | EPHB6/VWC2 ratio | GCST90314683 | 3.53 |
| 3617 | PRKRA levels | GCST90470331 | 3.53 |
| 3618 | BMP10 levels | GCST90468452 | 3.52 |
| 3619 | IGFBP3 levels | GCST90469529 | 3.52 |
| 3620 | COL6A3/OGN ratio | GCST90314177 | 3.52 |
| 3621 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T383 | ECGA000383 | 3.52 |
| 3622 | aseg global volume BrainSegNotVentSurf | GCST90002592 | 3.52 |
| 3623 | CLMP/TNFRSF19 ratio | GCST90314136 | 3.52 |
| 3624 | RNASE3 levels | GCST90470477 | 3.52 |
| 3625 | CRELD2/F2R ratio | GCST90314254 | 3.51 |
| 3626 | Liver enzyme levels (alkaline phosphatase) | GCST90013406 | 3.51 |
| 3627 | IDP dMRI TBSS L2 Cingulum cingulate gyrus L | GCST90004158 | 3.51 |
| 3628 | CD20 on IgD- CD24- B cell | GCST90001753 | 3.51 |
| 3629 | Crohns disease | GCST90468121 | 3.51 |
| 3630 | Total triglycerides levels | GCST003664 | 3.51 |
| 3631 | 1-palmitoyl-2-arachidonoyl-gpc (16:0/20:4n6) levels | GCST90200692 | 3.51 |
| 3632 | BCR/PLXNA4 ratio | GCST90313497 | 3.50 |
| 3633 | AHNAK2 levels | GCST90468260 | 3.50 |
| 3634 | IDP dMRI ProbtrackX ICVF str l | GCST90004398 | 3.50 |
| 3635 | Platelet distribution width | GCST004616 | 3.50 |
| 3636 | F-caffeinated/sweet liking (derived food-liking factor) | GCST90094720 | 3.50 |
| 3637 | Diacylglycerol_36:1_[M+H-H2O]1+ levels | GCST90060193 | 3.49 |
| 3638 | Non-albumin protein levels | UKBB00000503 | 3.49 |
| 3639 | AMIGO2 levels | GCST90468292 | 3.49 |
| 3640 | Apple juice liking | GCST90094690 | 3.49 |
| 3641 | SIRPB1 levels | GCST90470640 | 3.48 |
| 3642 | Ever unenthusiastic/disinterested for a whole week | Mental health | UKBB00000226 | 3.48 |
| 3643 | Red blood cell erythrocyte distribution width (UKB data field 30070) | GCST90468099 | 3.48 |
| 3644 | PDGFB/USP8 ratio | GCST90315633 | 3.48 |
| 3645 | METAP1D levels | GCST90469892 | 3.47 |
| 3646 | DBI/TMSB10 ratio | GCST90314414 | 3.47 |
| 3647 | rfMRI amplitudes (ICA100 node 11) | GCST90004599 | 3.47 |
| 3648 | Phosphatidylcholine_35:2_[M+H]1+/Phosphatidylethanolamine_38:2_[M+H]1+/Phosphatidate_40:3_[M+NH4]1+ levels | GCST90060325 | 3.47 |
| 3649 | IPCEF1/SMAD1 ratio | GCST90315185 | 3.47 |
| 3650 | Total esterified cholesterol levels (UKB data field 23415) | GCST90269512 | 3.47 |
| 3651 | Sarcoidosis | GCST90018698 | 3.47 |
| 3652 | APP/NID1 ratio | GCST90313326 | 3.47 |
| 3653 | Cholesteryl esters in small LDL (UKB data field 23548) | GCST90269645 | 3.46 |
| 3654 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T278 | ECGU000278 | 3.46 |
| 3655 | Use of disulfiram, acamprosate or naltrexone | FING00001410 | 3.46 |
| 3656 | HEXIM1/TBL1X ratio | GCST90315053 | 3.45 |
| 3657 | SMPD3 levels | GCST90470685 | 3.45 |
| 3658 | TNFSF13B levels | GCST90470920 | 3.45 |
| 3659 | Bone marrow fat fraction of lumbar vertebra 3 | GCST90652388 | 3.45 |
| 3660 | AGRP/CCN1 ratio | GCST90313202 | 3.45 |
| 3661 | Testosterone levels (UKB data field 30850) | GCST90468103 | 3.45 |
| 3662 | Calcium levels (UKB data field 30680) | GCST90468065 | 3.45 |
| 3663 | Excessive sweating | GCST006090 | 3.45 |
| 3664 | CXCL11/DKK1 ratio | GCST90314334 | 3.44 |
| 3665 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T386 | ECGA000386 | 3.44 |
| 3666 | wg lh intensity-contrast rostralanteriorcingulate | GCST90003817 | 3.44 |
| 3667 | GOPC/IRAK4 ratio | GCST90314954 | 3.44 |
| 3668 | MGLL/MITD1 ratio | GCST90315436 | 3.44 |
| 3669 | Mean corpuscular hemoglobin | GCST90018744 | 3.43 |
| 3670 | Omega-6 fatty acids to total fatty acids percentage | GCST90502529 | 3.43 |
| 3671 | DAB2/GRAP2 ratio | GCST90314364 | 3.43 |
| 3672 | Coriander liking | GCST90094744 | 3.43 |
| 3673 | IDP dMRI TBSS ICVF Superior corona radiata R | GCST90004351 | 3.43 |
| 3674 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T387 | ECGA000387 | 3.43 |
| 3675 | EDAR/TMSB10 ratio | GCST90314590 | 3.42 |
| 3676 | T1 FreeSurfer DKT rh lingual area | GCST90384297 | 3.42 |
| 3677 | DKK1 levels | GCST90468997 | 3.42 |
| 3678 | PGLYRP1 levels | GCST90470219 | 3.41 |
| 3679 | MS-disease / Multiple Sclerosis | FING00000839 | 3.41 |
| 3680 | aseg rh number HolesBeforeFixing | GCST90002647 | 3.41 |
| 3681 | Phosphate | Blood biochemistry | UKBB00000644 | 3.40 |
| 3682 | STX8 levels | GCST90470776 | 3.40 |
| 3683 | Father's age at death | Family history | UKBB00000241 | 3.40 |
| 3684 | C3 levels | GCST90281041 | 3.40 |
| 3685 | Heel quantitative ultrasound index (QUI), direct entry (right) | Bone-densitometry of heel | UKBB00000323 | 3.40 |
| 3686 | Heel bone mineral density (BMD) T-score, automated (right) | Bone-densitometry of heel | UKBB00000317 | 3.39 |
| 3687 | Medication use (glucocorticoids) | GCST90018780 | 3.39 |
| 3688 | Influenza and pneumonia | FING00000679 | 3.39 |
| 3689 | Free cholesterol in medium VLDL (UKB data field 23507) | GCST90269604 | 3.39 |
| 3690 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T385 | ECGU000385 | 3.39 |
| 3691 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T219 | ECGA000219 | 3.39 |
| 3692 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T380 | ECGU000380 | 3.38 |
| 3693 | Abnormality of gait (PheCode 350.2) | GCST90475841 | 3.38 |
| 3694 | IGFBP6/PTGDS ratio | GCST90315137 | 3.37 |
| 3695 | Cholesterol to total lipids in chylomicrons and extremely large VLDL percentage (UKB data field 23580) | GCST90269677 | 3.37 |
| 3696 | Placental weight (fetal genotype, adjusted for sex) | GCST90275197 | 3.37 |
| 3697 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T304 | ECGA000304 | 3.36 |
| 3698 | DTI autoptx L3 ptr l tract | GCST90385212 | 3.36 |
| 3699 | IDP dMRI ProbtrackX ICVF slf r | GCST90004397 | 3.36 |
| 3700 | CDKN1A/TACC3 ratio | GCST90313975 | 3.35 |
| 3701 | Hypertrophy of breast | FING00000644 | 3.35 |
| 3702 | CD55/ITGB1 ratio | GCST90313846 | 3.35 |
| 3703 | DTI autoptx MD fmi tract | GCST90385231 | 3.35 |
| 3704 | Crohn's disease NAS | FING00000367 | 3.35 |
| 3705 | Placental weight (paternal genotype, adjusted for sex) | GCST90275199 | 3.35 |
| 3706 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T294 | ECGU000294 | 3.35 |
| 3707 | Percentage of FA2G1 in total neutral plasma glycans (GPn) (GP61) | GCST90668739 | 3.34 |
| 3708 | CD84/DKK1 ratio | GCST90313911 | 3.34 |
| 3709 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T284 | ECGA000284 | 3.34 |
| 3710 | F7 levels | GCST90469171 | 3.34 |
| 3711 | PLXNB3/SNAP23 ratio | GCST90315693 | 3.34 |
| 3712 | EDAR/F11R ratio | GCST90314576 | 3.34 |
| 3713 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T384 | ECGU000384 | 3.34 |
| 3714 | Ratio of polyunsaturated fatty acids to total fatty acids | GCST90092941 | 3.34 |
| 3715 | KIR2DL3 levels | GCST90469685 | 3.33 |
| 3716 | BPIFA2 levels | GCST90468461 | 3.33 |
| 3717 | DAG1/DBNL ratio | GCST90314372 | 3.33 |
| 3718 | Two-hour glucose | GCST90002227 | 3.33 |
| 3719 | TNFRSF8 levels | GCST90470915 | 3.33 |
| 3720 | GPD1 levels | GCST90469388 | 3.33 |
| 3721 | Snoring | GCST009762 | 3.32 |
| 3722 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T429 | ECGU000429 | 3.32 |
| 3723 | CAPG levels | GCST90468537 | 3.32 |
| 3724 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T445 | ECGA000445 | 3.32 |
| 3725 | Bone marrow fat fraction of lumbar vertebra 4 | GCST90652389 | 3.32 |
| 3726 | ITGA2 levels | GCST90469634 | 3.32 |
| 3727 | Free cholesterol in very large VLDL | GCST90500581 | 3.32 |
| 3728 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T383 | ECGU000383 | 3.31 |
| 3729 | red cell diameter width (RDW, mean, inv-norm transformed) | GCST90476361 | 3.31 |
| 3730 | ANGPTL3 levels | GCST90468304 | 3.31 |
| 3731 | Emphysema | FING00000496 | 3.31 |
| 3732 | Total cholesterol levels in HDL | GCST90132681 | 3.31 |
| 3733 | Anterior diffusion tensor imaging along the perivascular space index | GCST90455543 | 3.31 |
| 3734 | DTI TBSS L3 Superior cerebellar peduncle R | GCST90384536 | 3.31 |
| 3735 | CST3/TIMP1 ratio | GCST90314300 | 3.31 |
| 3736 | Platelet count | GCST90018749 | 3.30 |
| 3737 | Modified Stumvoll Insulin Sensitivity Index (model adjusted for BMI) | GCST003658 | 3.30 |
| 3738 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T105 | ECGU000105 | 3.30 |
| 3739 | Urine glycocholenate sulfate* levels in chronic kidney disease | GCST90265292 | 3.30 |
| 3740 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 24) | GCST90320587 | 3.30 |
| 3741 | LGALS3 levels | GCST90012009 | 3.29 |
| 3742 | CRELD2/NUCB2 ratio | GCST90314256 | 3.29 |
| 3743 | PPME1/PSMD9 ratio | GCST90315705 | 3.29 |
| 3744 | Osteoporosis, osteopenia and pathological fracture (PheCode 743) | GCST90476258 | 3.29 |
| 3745 | Hands-free device/speakerphone use with mobile phone in last 3 month | Electronic device use | UKBB00000304 | 3.29 |
| 3746 | BTN2A1/IFNGR1 ratio | GCST90313543 | 3.28 |
| 3747 | wg lh intensity-contrast entorhinal | GCST90003797 | 3.28 |
| 3748 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T303 | ECGU000303 | 3.28 |
| 3749 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T378 | ECGU000378 | 3.28 |
| 3750 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T379 | ECGU000379 | 3.28 |
| 3751 | PBLD levels | GCST90470163 | 3.28 |
| 3752 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T384 | ECGA000384 | 3.28 |
| 3753 | GALNT10/IGSF3 ratio | GCST90314914 | 3.28 |
| 3754 | Cholesteryl ester levels in small LDL | GCST90092958 | 3.27 |
| 3755 | CXCL5 levels | GCST90468932 | 3.27 |
| 3756 | X-11444 metabolite level | GCST90616545 | 3.27 |
| 3757 | Mean platelet volume during second trimester of pregnancy | GCST90302230 | 3.27 |
| 3758 | CEACAM5 levels | GCST90468696 | 3.27 |
| 3759 | Volume of right medial nucleus | GCST90474925 | 3.27 |
| 3760 | GCNT1 levels | GCST90469319 | 3.26 |
| 3761 | NOTCH1/TIE1 ratio | GCST90315546 | 3.26 |
| 3762 | Ulcerative colitis | GCST004133 | 3.26 |
| 3763 | HHIP levels | GCST90617097 | 3.26 |
| 3764 | Mean diameter of VLDL particles | GCST90132734 | 3.26 |
| 3765 | Total cholesterol levels (UKB data field 23400) | GCST90269497 | 3.26 |
| 3766 | Red cell distribution width | GCST004621 | 3.25 |
| 3767 | QC rfMRI cleaned inverse tSNR | GCST90006358 | 3.25 |
| 3768 | Cystatin C production | GCST90267986 | 3.25 |
| 3769 | Degeneration of macula and posterior pole of retina (PheCode 362.2) | GCST90475849 | 3.25 |
| 3770 | Basophil count | GCST90018726 | 3.25 |
| 3771 | SH2B3 levels | GCST90470616 | 3.24 |
| 3772 | IDP dMRI TBSS FA Retrolenticular part of internal capsule L | GCST90003898 | 3.24 |
| 3773 | Fracture of radius and ulna (PheCode 803.2) | GCST90476280 | 3.24 |
| 3774 | IL6ST levels | GCST90469603 | 3.23 |
| 3775 | GIMAP7 levels | GCST90469345 | 3.23 |
| 3776 | Platelet count during third trimester of pregnancy | GCST90302226 | 3.23 |
| 3777 | DNAJB14 levels | GCST90240952 | 3.23 |
| 3778 | Degree of unsaturation | GCST90502734 | 3.23 |
| 3779 | LONP1 levels | GCST90469785 | 3.23 |
| 3780 | IDP dMRI TBSS L1 Sagittal stratum L | GCST90004106 | 3.22 |
| 3781 | ENG levels | GCST90469108 | 3.22 |
| 3782 | PLXDC2 levels | GCST90470264 | 3.22 |
| 3783 | Systemic connective tissue disorders | FING00001350 | 3.22 |
| 3784 | FGF23 levels | GCST90469223 | 3.21 |
| 3785 | CD101 levels | GCST90468596 | 3.21 |
| 3786 | C20:4 Lysophosphatidylcholine levels in chronic kidney disease | GCST90257570 | 3.21 |
| 3787 | PSMD9/UBAC1 ratio | GCST90315735 | 3.21 |
| 3788 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T385 | ECGA000385 | 3.21 |
| 3789 | MTSS2 levels | GCST90469961 | 3.20 |
| 3790 | Cholesteryl esters to total lipids in chylomicrons and extremely large VLDL percentage (UKB data field 23581) | GCST90269678 | 3.20 |
| 3791 | Phosphate levels (UKB data field 30810) | GCST90468094 | 3.19 |
| 3792 | CD36 levels | GCST90468627 | 3.19 |
| 3793 | CLSTN3 levels | GCST90468790 | 3.19 |
| 3794 | Other eye problems | Eyesight | UKBB00000610 | 3.19 |
| 3795 | IDP dMRI ProbtrackX L3 ifo l | GCST90004312 | 3.19 |
| 3796 | DTI TBSS MO Middle cerebellar peduncle | GCST90384620 | 3.19 |
| 3797 | IDP dMRI ProbtrackX ISOVF ifo l | GCST90004537 | 3.18 |
| 3798 | Hemangioma of skin and subcutaneous tissue (PheCode 228.1) | GCST90475633 | 3.18 |
| 3799 | EIF4G1/PLA2G4A ratio | GCST90314638 | 3.18 |
| 3800 | MIA levels | GCST90469903 | 3.18 |
| 3801 | Hypertrophic scar | FING00000642 | 3.18 |
| 3802 | Erysipelas | FING00000518 | 3.17 |
| 3803 | Synonym | Fluid intelligence / reasoning | UKBB00000802 | 3.17 |
| 3804 | wg rh intensity-contrast parstriangularis | GCST90003846 | 3.17 |
| 3805 | IL2RA/NCR1 ratio | GCST90315161 | 3.17 |
| 3806 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 102) | GCST90320921 | 3.17 |
| 3807 | CALCOCO1/PFKFB2 ratio | GCST90313608 | 3.17 |
| 3808 | Excessive hairiness | GCST006095 | 3.17 |
| 3809 | Urine methylsuccinoylcarnitine levels in chronic kidney disease | GCST90265509 | 3.17 |
| 3810 | UGDH levels | GCST90471006 | 3.17 |
| 3811 | Ulcerative colitis | GCST90475322 | 3.17 |
| 3812 | IDP dMRI ProbtrackX ISOVF cgc l | GCST90004529 | 3.16 |
| 3813 | NFU1 levels | GCST90470040 | 3.16 |
| 3814 | CTSF/NAAA ratio | GCST90314314 | 3.16 |
| 3815 | IDP dMRI ProbtrackX L1 cgc l | GCST90004250 | 3.16 |
| 3816 | F-sweetened coffee drink liking (derived food-liking factor) | GCST90094853 | 3.16 |
| 3817 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T102 | ECGU000102 | 3.16 |
| 3818 | IDP dMRI ProbtrackX MD cst l | GCST90004227 | 3.16 |
| 3819 | Multiple myeloma | GCST90624747 | 3.16 |
| 3820 | TNR levels | GCST90470929 | 3.16 |
| 3821 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T379 | ECGA000379 | 3.16 |
| 3822 | DNAJB1/STIP1 ratio | GCST90314513 | 3.15 |
| 3823 | ACVRL1/EFNA4 ratio | GCST90313156 | 3.15 |
| 3824 | DKK1/PDGFA ratio | GCST90314475 | 3.15 |
| 3825 | Frequency of heavy DIY in last 4 weeks | Physical activity | UKBB00000263 | 3.14 |
| 3826 | Plasma betaine levels in chronic kidney disease | GCST90264858 | 3.14 |
| 3827 | PATE4 levels | GCST90242405 | 3.14 |
| 3828 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T447 | ECGA000447 | 3.14 |
| 3829 | Nonalcoholic fatty liver disease | GCST90091033 | 3.13 |
| 3830 | PTPRK levels | GCST90470383 | 3.13 |
| 3831 | Congestive heart failure (CHF) NOS (PheCode 428.1) | GCST90475982 | 3.13 |
| 3832 | aparc-DKTatlas lh volume caudalmiddlefrontal | GCST90002864 | 3.13 |
| 3833 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T386 | ECGU000386 | 3.13 |
| 3834 | EFNA4/VWC2 ratio | GCST90314607 | 3.13 |
| 3835 | Androsterone sulfate levels | GCST90200674 | 3.12 |
| 3836 | PLA2G4A/SNX9 ratio | GCST90315670 | 3.12 |
| 3837 | Smoking and associated risk behaviours (confirmatory factor analysis Factor 6) | GCST90309341 | 3.12 |
| 3838 | CCL28 levels | GCST90468580 | 3.12 |
| 3839 | CD209/CLEC14A ratio | GCST90313749 | 3.12 |
| 3840 | Triglycerides to total lipids in medium VLDL percentage (UKB data field 23598) | GCST90269695 | 3.12 |
| 3841 | X-12707 levels | GCST90200502 | 3.11 |
| 3842 | DCTN1/ERBIN ratio | GCST90314429 | 3.11 |
| 3843 | CPXM1/DKK1 ratio | GCST90314218 | 3.11 |
| 3844 | Suppurative and unspecified otitis media | FING00001346 | 3.11 |
| 3845 | T1 FreeSurfer BA lh BA2 exvivo volume | GCST90385534 | 3.10 |
| 3846 | Right-hemisphere salience/ventral attention network to pallidum white-matter structural connectivity | GCST90302820 | 3.10 |
| 3847 | aparc-Desikan lh volume caudalmiddlefrontal | GCST90002771 | 3.10 |
| 3848 | VASH1 levels | GCST90471026 | 3.10 |
| 3849 | aparc-Desikan lh volume parsopercularis | GCST90002785 | 3.10 |
| 3850 | Hypertension | GCST90086092 | 3.10 |
| 3851 | IDP T1 FAST ROIs R front operc cortex | GCST90002532 | 3.09 |
| 3852 | CCL4 levels | GCST90274770 | 3.09 |
| 3853 | N-acetylglycine levels | GCST90243561 | 3.09 |
| 3854 | PRSS53 levels | GCST90470344 | 3.09 |
| 3855 | Red cell distribution width | GCST90025988 | 3.09 |
| 3856 | RETN levels | GCST90470457 | 3.09 |
| 3857 | Spicy food liking | GCST90094846 | 3.09 |
| 3858 | S100A12 levels | GCST90470513 | 3.09 |
| 3859 | MTIF3 levels | GCST90469957 | 3.09 |
| 3860 | MYBPC1 levels | GCST90469969 | 3.09 |
| 3861 | DIABLO/GRAP2 ratio | GCST90314466 | 3.08 |
| 3862 | Red blood cell (erythrocyte) distribution width | Blood count | UKBB00000748 | 3.08 |
| 3863 | NUCB2/RSPO3 ratio | GCST90315575 | 3.08 |
| 3864 | IDP dMRI TBSS FA Anterior corona radiata R | GCST90003899 | 3.08 |
| 3865 | Lysoalkylphosphatidylcholine (O-24:0) levels | GCST90024812 | 3.07 |
| 3866 | Hemoglobin A1c levels | GCST90018738 | 3.07 |
| 3867 | Macular degeneration | GCST90475386 | 3.07 |
| 3868 | Triglyceride levels in very small VLDL | GCST90132669 | 3.07 |
| 3869 | Other specified disorders of external ear | FING00001104 | 3.07 |
| 3870 | Triglycerides to total lipids in IDL percentage (UKB data field 23613) | GCST90269710 | 3.07 |
| 3871 | Heel bone mineral density (BMD) (right) | Bone-densitometry of heel | UKBB00000314 | 3.06 |
| 3872 | CD244 levels | GCST90468611 | 3.06 |
| 3873 | ABL1 levels | GCST90468190 | 3.06 |
| 3874 | RCC1 levels | GCST90470443 | 3.06 |
| 3875 | Fluid intelligence score (baseline) | GCST90565842 | 3.06 |
| 3876 | VEGFA levels | GCST90471034 | 3.06 |
| 3877 | Ratio of bis-allylic bonds to double bonds in lipids | GCST90132744 | 3.05 |
| 3878 | CDKN1A/FXN ratio | GCST90313971 | 3.05 |
| 3879 | CD46/SIAE ratio | GCST90313835 | 3.05 |
| 3880 | MMP8/TGFA ratio | GCST90315466 | 3.05 |
| 3881 | Endometriosis of rectovaginal septum and vagina | FING00000503 | 3.05 |
| 3882 | CTSV levels | GCST90468917 | 3.04 |
| 3883 | ERBB4/NELL1 ratio | GCST90314691 | 3.04 |
| 3884 | ALB levels | GCST90018725 | 3.04 |
| 3885 | X-11550 levels | GCST90243648 | 3.04 |
| 3886 | CD302/IL12A_IL12B ratio | GCST90313806 | 3.03 |
| 3887 | DTI TBSS MD Posterior corona radiata R | GCST90384598 | 3.03 |
| 3888 | LAP3 levels | GCST90469737 | 3.03 |
| 3889 | Lysoalkylphosphatidylcholine (O-24:1) levels | GCST90024198 | 3.03 |
| 3890 | FGF5 levels | GCST90469226 | 3.03 |
| 3891 | IL1RL1 levels | GCST90469574 | 3.03 |
| 3892 | Degree of unsaturation | GCST90502736 | 3.03 |
| 3893 | PENK levels | GCST90470208 | 3.03 |
| 3894 | CRADD/EDAR ratio | GCST90314235 | 3.03 |
| 3895 | CNTN1/EGFR ratio | GCST90314162 | 3.03 |
| 3896 | ADAMTS15/CLMP ratio | GCST90313170 | 3.02 |
| 3897 | Umbilical hernia (PheCode 550.4) | GCST90476062 | 3.02 |
| 3898 | REG1A/TFF3 ratio | GCST90315764 | 3.02 |
| 3899 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T304 | ECGU000304 | 3.01 |
| 3900 | CHGB levels | GCST90468742 | 3.01 |
| 3901 | lymphocyte (absolute count, mean, inv-norm transformed) | GCST90475426 | 3.01 |
| 3902 | SELE levels | GCST90470566 | 3.01 |
| 3903 | 3-methyl-2-oxobutyrate levels | GCST90199677 | 3.01 |
| 3904 | First line medication for Crohn's disease | FING00000544 | 3.01 |
| 3905 | KLK13 levels | GCST90469699 | 3.01 |
| 3906 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T378 | ECGA000378 | 3.01 |
| 3907 | Sphingomyelin (d18:1/16:0) levels | GCST90025744 | 3.01 |
| 3908 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T288 | ECGA000288 | 3.00 |
| 3909 | NUCB2 levels | GCST90470101 | 3.00 |
| 3910 | TIMM10 levels | GCST90470867 | 3.00 |
| 3911 | Other/unspecified dorsalgia | FING00001124 | 3.00 |
| 3912 | ARHGEF1 levels | GCST90468359 | 2.99 |
| 3913 | MATN2/SCARA5 ratio | GCST90315388 | 2.99 |
| 3914 | Pregnenetriol disulfate levels | GCST90200238 | 2.99 |
| 3915 | Degree of unsaturation | GCST90502224 | 2.99 |
| 3916 | ENG/TNFRSF10C ratio | GCST90314650 | 2.99 |
| 3917 | Reticulocyte count | GCST90002405 | 2.98 |
| 3918 | RARRES2/TFPI ratio | GCST90315760 | 2.98 |
| 3919 | AmygNuclei lh volume Cortical-nucleus | GCST90002654 | 2.98 |
| 3920 | CD40LG/MPIG6B ratio | GCST90313825 | 2.98 |
| 3921 | XCL1 levels | GCST90471081 | 2.98 |
| 3922 | FYB1 levels | GCST90469284 | 2.97 |
| 3923 | BIN2/TMSB10 ratio | GCST90313515 | 2.97 |
| 3924 | T1 FreeSurfer a2009s rh S collat transv ant area | GCST90384939 | 2.97 |
| 3925 | Enthesopathy (PheCode 726.1) | GCST90476239 | 2.97 |
| 3926 | DLL1/EFEMP1 ratio | GCST90314494 | 2.97 |
| 3927 | Operative procedures - Anastomosis of mammary artery to left anterior descending coronary artery | Summary Operations | UKBB00000571 | 2.96 |
| 3928 | Bioavailable testosterone levels | GCST90012103 | 2.96 |
| 3929 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T293 | ECGU000293 | 2.96 |
| 3930 | Oily fish intake | Diet | UKBB00000547 | 2.96 |
| 3931 | Concentration of VLDL particles | GCST90500250 | 2.96 |
| 3932 | A1BG levels | GCST90468185 | 2.95 |
| 3933 | IDP dMRI TBSS ICVF Cingulum hippocampus R | GCST90004363 | 2.95 |
| 3934 | Total lipids in medium LDL (UKB data field 23538) | GCST90269635 | 2.95 |
| 3935 | Cholesteryl Esters in Medium VLDL | GCST90498928 | 2.95 |
| 3936 | F-coffee/alcohol liking (derived food-liking factor) | GCST90094737 | 2.94 |
| 3937 | rfMRI connectivity (ICA100 edge 1090) | GCST90005943 | 2.94 |
| 3938 | Leucine levels | GCST90243405 | 2.94 |
| 3939 | Mosaic chromosomal alteration of the Y chromosome | GCST90165289 | 2.94 |
| 3940 | PF4 levels | GCST90470211 | 2.94 |
| 3941 | Osteopenia or other disorder of bone and cartilage (PheCode 743.9) | GCST90476261 | 2.93 |
| 3942 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T376 | ECGA000376 | 2.93 |
| 3943 | Testosterone levels | GCST90483487 | 2.93 |
| 3944 | Other non-toxic goitre | Disorders of thyroid gland | UKBB00000617 | 2.93 |
| 3945 | IDP dMRI ProbtrackX FA fmi | GCST90003936 | 2.93 |
| 3946 | IDP dMRI ProbtrackX FA cst r | GCST90003934 | 2.93 |
| 3947 | CLPS/PLA2G1B ratio | GCST90314140 | 2.93 |
| 3948 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T438 | ECGA000438 | 2.93 |
| 3949 | End-diastolic bi-ventricular shape (principal component 10) | GCST90448489 | 2.92 |
| 3950 | PLXNA4/USP8 ratio | GCST90315690 | 2.92 |
| 3951 | ABO levels | GCST90468191 | 2.92 |
| 3952 | Benign neoplasm of skin (PheCode 216) | GCST90475620 | 2.92 |
| 3953 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 41) | GCST90320860 | 2.92 |
| 3954 | Congenital iodine-deficiency syndrome/hypothyroidism | FING00000328 | 2.92 |
| 3955 | Familial combined hyperlipidemia defined by Dutch criteria | GCST90104005 | 2.92 |
| 3956 | CD46/TNFRSF14 ratio | GCST90313838 | 2.92 |
| 3957 | CASP8/RILP ratio | GCST90313657 | 2.92 |
| 3958 | CHRDL2 levels | GCST90468751 | 2.92 |
| 3959 | Multiple myeloma and malignant plasma cell neoplasms (controls excluding all cancers) | FING00000843 | 2.92 |
| 3960 | Mean platelet volume during third trimester of pregnancy | GCST90302231 | 2.91 |
| 3961 | IDP dMRI ProbtrackX FA ptr l | GCST90003944 | 2.91 |
| 3962 | NECTIN2/SDC1 ratio | GCST90315529 | 2.91 |
| 3963 | PRTN3/RETN ratio | GCST90315734 | 2.91 |
| 3964 | BMP7 levels | GCST90088157 | 2.91 |
| 3965 | SLMAP levels | GCST90470673 | 2.91 |
| 3966 | IGFBP4/OGN ratio | GCST90315134 | 2.91 |
| 3967 | SPARCL1 levels | GCST90470717 | 2.90 |
| 3968 | IDP dMRI TBSS ICVF Fornix cres+Stria terminalis R | GCST90004365 | 2.90 |
| 3969 | SFRP1 levels | GCST90470610 | 2.90 |
| 3970 | PRRT3 levels | GCST90470340 | 2.90 |
| 3971 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T436 | ECGA000436 | 2.90 |
| 3972 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 106) | GCST90320925 | 2.90 |
| 3973 | Omega-6 fatty acids to total fatty acids percentage | GCST90502541 | 2.90 |
| 3974 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T317 | ECGU000317 | 2.90 |
| 3975 | LYPD3 levels | GCST90469828 | 2.89 |
| 3976 | HBEGF/PDGFB ratio | GCST90315034 | 2.89 |
| 3977 | Adhesive capsulitis of shoulder | FING00000043 | 2.89 |
| 3978 | CSF3R levels | GCST90468885 | 2.89 |
| 3979 | Dyslipidemia | GCST90086077 | 2.89 |
| 3980 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T375 | ECGA000375 | 2.89 |
| 3981 | Citrate levels | GCST90092813 | 2.89 |
| 3982 | LAT/MANF ratio | GCST90315284 | 2.88 |
| 3983 | Porridge liking | GCST90094815 | 2.88 |
| 3984 | LBR levels | GCST90469744 | 2.88 |
| 3985 | Polyunsaturated fatty acids to total fatty acids percentage | GCST90502632 | 2.88 |
| 3986 | Other and unspecified nerve root and plexus disorders, also in other diseases | FING00000944 | 2.88 |
| 3987 | Metabolic syndrome | GCST90444487 | 2.88 |
| 3988 | Cardiorespiratory fitness (vo2 max) | GCST90093317 | 2.88 |
| 3989 | Cholesteryl ester levels in medium LDL | GCST90092906 | 2.88 |
| 3990 | Frozen shoulder | GCST90000513 | 2.88 |
| 3991 | MOG/RTBDN ratio | GCST90315476 | 2.87 |
| 3992 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T305 | ECGU000305 | 2.87 |
| 3993 | TNFRSF14/TNFRSF1A ratio | GCST90315935 | 2.87 |
| 3994 | aseg global volume CC-Anterior | GCST90002611 | 2.87 |
| 3995 | LIFR levels | GCST90469769 | 2.87 |
| 3996 | End-diastolic bi-ventricular shape (principal component 1) | GCST90448480 | 2.87 |
| 3997 | IDP dMRI ProbtrackX ICVF cst l | GCST90004383 | 2.86 |
| 3998 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T289 | ECGU000289 | 2.86 |
| 3999 | LY9 levels | GCST90469824 | 2.86 |
| 4000 | DNMBP/WWP2 ratio | GCST90314522 | 2.86 |